Abstract | CONTEXT: OBJECTIVE: We examined the effect and potential molecular action mechanism of GJT in a mouse model of COPD induced by cigarette smoke (CS) plus lipopolysaccharide (LPS). MATERIALS AND METHODS:
COPD was induced in C57BL/6J mice via daily exposure to CS for 1 h for 8 weeks and intranasal administration of LPS on weeks 1, 3, 5, and 7. GJT (100 or 200 mg/kg) or roflumilast (5 mg/kg) was administrated daily for the final 4 weeks of COPD induction. RESULTS: DISCUSSION AND CONCLUSIONS: These results demonstrate that GJT prevents the lung inflammation and airway remodelling induced by CS plus LPS exposure in mice, suggesting that GJT may have therapeutic potential for the treatment of COPD.
|
Authors | Eun Bok Baek, Yu Jin Kim, Jin-Hyung Rho, Eun-Ju Hong, Mee-Young Lee, Hyo-Jung Kwun |
Journal | Pharmaceutical biology
(Pharm Biol)
Vol. 60
Issue 1
Pg. 2040-2048
(Dec 2022)
ISSN: 1744-5116 [Electronic] England |
PMID | 36267048
(Publication Type: Journal Article)
|
Chemical References |
- Lipopolysaccharides
- Tumor Necrosis Factor-alpha
- STAT3 Transcription Factor
- NF-kappa B
- Matrix Metalloproteinase 9
- Interleukin-8
- Anti-Inflammatory Agents
- Transforming Growth Factor beta
|
Topics |
- Mice
- Animals
- Lipopolysaccharides
(toxicity)
- Tumor Necrosis Factor-alpha
(metabolism)
- STAT3 Transcription Factor
(metabolism)
- NF-kappa B
(metabolism)
- Cigarette Smoking
- Matrix Metalloproteinase 9
(metabolism)
- Interleukin-8
(metabolism, pharmacology, therapeutic use)
- Mice, Inbred C57BL
- Pulmonary Disease, Chronic Obstructive
(chemically induced)
- Lung
- Nicotiana
- Disease Models, Animal
- Anti-Inflammatory Agents
(therapeutic use)
- Transforming Growth Factor beta
(metabolism)
|